ARDELYX, INC. Current Income Tax Expense (Benefit)
ARDELYX, INC. (ARDX) reported Current Income Tax Expense (Benefit) of $969.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-02-19
- ARDELYX, INC. current income tax expense (benefit) for fiscal 2025 was $969.00K, a 264.29% increase from fiscal 2024.
- ARDELYX, INC. current income tax expense (benefit) for fiscal 2024 was $266.00K, a 51.37% decline from fiscal 2023.
- ARDELYX, INC. current income tax expense (benefit) for fiscal 2023 was $547.00K, a 6737.50% increase from fiscal 2022.
- ARDELYX, INC. current income tax expense (benefit) for fiscal 2022 was $8.00K, a 100.00% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $969.00K 10-K · filed 2026-02-19 |
| 2024-12-31 | $266.00K 10-K · filed 2026-02-19 |
| 2023-12-31 | $547.00K 10-K · filed 2026-02-19 |
| 2022-12-31 | $8.00K 10-K · filed 2025-02-20 |
| 2021-12-31 | $4.00K 10-K · filed 2024-02-22 |
| 2020-12-31 | $2.00K 10-K · filed 2023-03-02 |
| 2019-12-31 | $303.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | $4.00K 10-K · filed 2021-03-08 |
| 2017-12-31 | $1.21M 10-K · filed 2020-03-06 |
| 2015-12-31 | -$29.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |